Dragonfly Therapeutics Inc, a clinical stage biotechnology company, announced on Tuesday that it has dosed its first subject in a Phase 1/1b study of the firm's proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumours.

DF6215 is the second in a pipeline of cytokines Dragonfly is developing to address the high unmet need in patients with advanced cancer and other diseases. This is the seventh Dragonfly-developed and fourth Dragonfly-owned drug, in the clinic.

Dragonfly's DF6215 Phase 1/1b clinical trial is a first-in-human, multi-part, open-label study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF6215 in patients with advanced (unresectable, recurrent, or metastatic) solid tumours. DF6215-001 is currently recruiting at multiple sites in the US, with sites in additional regions scheduled to open in 2024.